Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and cilostazol

rosiglitazone has been researched along with cilostazol in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Hong, KW; Kim, CD; Kim, EK; Kim, KY; Lee, JH; Lee, WS; Park, SY; Yun, SJ1
Potharaju, S; Raghavan, R; Thappali, RS; Vakkalanka, VS; Varanasi, VS; Veeraraghavan, S1

Reviews

1 review(s) available for rosiglitazone and cilostazol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for rosiglitazone and cilostazol

ArticleYear
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription.
    Atherosclerosis, 2008, Volume: 201, Issue:2

    Topics: 3T3-L1 Cells; Anilides; Animals; Cell Differentiation; Chlorocebus aethiops; Cilostazol; COS Cells; Fibroblasts; Glucose; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Mice; Phosphodiesterase Inhibitors; PPAR gamma; Rosiglitazone; Tetrazoles; Thiazolidinediones

2008
Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics.
    Arzneimittel-Forschung, 2008, Volume: 58, Issue:6

    Topics: Animals; Area Under Curve; Chromatography, High Pressure Liquid; Cilostazol; Drug Interactions; Half-Life; Hypoglycemic Agents; Male; Platelet Aggregation Inhibitors; Quality Control; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Rosiglitazone; Spectrophotometry, Ultraviolet; Tetrazoles; Thiazolidinediones

2008